P16 (INK4a) has clinicopathological and prognostic impact on oropharynx and larynx squamous cell carcinoma

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 12, 2012, Pages 1327-1333

  Silva, S D ^a,b,c   Nonogaki, S ^a   Soares, F A ^a,d   Kowalski, L P ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Head and neck cancer; P16; Prognostic value; Squamous cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872316388     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500140     Document Type: Article

References (32)

1. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dal- bagni G, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995; 87: 1524-1529.
2. Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 1995; 11: 635-645.
3. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associ- ated with survival of head and neck cancer. Infect Agent Cancer 2010; 5: 4.
4. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Jans- sen JW, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755-760.
5. Poznic M. Retinoblastoma protein: a central processing unit. J Biosci 2009; 34: 305-312.
6. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-1748.
7. Takeuchi S, Seriu T, van Dongen JJ, Szczepanski T, Tsu- kasaki K, Takeuchi N, et al. Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene 2003; 22: 6970-6976.
8. Rother J, Jones D. Molecular markers of tumor progression in melanoma. Curr Genomics 2009; 10: 231-239.
9. Sanchez-Fayos Calabuig P, Martin Relloso MJ, Porres Cubero JC. [Genetic profle and molecular bases of pancreatic carcinogenesis]. Gastroenterol Hepatol 2007; 30: 592-596.
10. Salam I, Hussain S, Mir MM, Dar NA, Abdullah S, Siddiqi MA, et al. Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir valley: a high-risk area. Mol Cell Biochem 2009; 332: 51-58.
11. Ye Y, Wang D, Su C, Rong T, Guo A. Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by sus- pension microarray. Genet Mol Res 2009; 8: 1509-1518.
12. Attaleb M, El hamadani W, Khyatti M, Benbacer L, Benchek- roun N, Benider A, et al. Status of p16(INK4a) and E-cad- herin gene promoter methylation in Moroccan patients with cervical carcinoma. Oncol Res 2009; 18: 185-192.
13. Koscielny S, Dahse R, Ernst G, von Eggeling F. The prog- nostic relevance of p16 inactivation in head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2007; 69: 30-36.
14. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in can- cer progression. Exp Cell Res 2001; 264: 42-55.
15. Zhou X, Temam S, Oh M, Pungpravat N, Huang BL, Mao L, et al. Global expression-based classifcation of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia 2006; 8: 925-932.
16. Wahi P, Cohen B, Luthra U, Torloni H. Histological typing of oral and oropharyngeal tumours. Geneva: World Health Organization; 1971.
17. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profling of tumor specimens. Nat Med 1998; 4: 844-847.
18. Sinha P, Bahadur S, Thakar A, Matta A, Macha M, Ralhan R, et al. Signifcance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. Head Neck 2009; 31: 1423-1430.
19. Takeuchi S, Bartram CR, Wada M, Reiter A, Hatta Y, Seriu T, et al. Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res 1995; 55: 5377-5382.
20. Liggett WH Jr, Sidransky D. Role of the p16 tumor suppres- sor gene in cancer. J Clin Oncol 1998; 16: 1197-1206.
21. Li AF, Li AC, Tsay SH, Li WY, Liang WY, Chen JY. Alterations in the p16INK4a/cyclin D1/RB pathway in gastrointestinal tract endocrine tumors. Am J Clin Pathol 2008; 130: 535-542.
22. Richmond-Sinclair NM, Lee E, Cummings MC, Williamson R, Muller K, Green AC, et al. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunos- taining in cutaneous melanomas. Melanoma Res 2008; 18: 336-345.
23. Hoffmann M, Ihloff AS, Gorogh T, Weise JB, Fazel A, Krams M, et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-1602.
24. Nichols AC, Faquin WC, Westra WH, Mroz EA, Begum S, Clark JR, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 140: 228-234.
25. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang SC, Pater MM, et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997; 75: 1410-1416.
26. Singhi AD, Westra WH. Comparison of human papilloma- virus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116: 2166-2173.
27. Kim YT, Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 2005; 46: 597-613.
28. Kong CS, Narasimhan B, Cao H, Kwok S, Erickson JP, Koong A, et al. The relationship between human papilloma- virus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74: 553-561.
29. Lim KP, Hamid S, Lau SH, Teo SH, Cheong SC. HPV infec- tion and the alterations of the pRB pathway in oral carcino- genesis. Oncol Rep 2007; 17: 1321-1326.
30. dos Reis PP, Poli-Frederico RC, dos Santos RM, Nishimoto IN, Kowalski LP, Rogatto SR. Distinct regions of loss of heterozygosity on 22q in different sites of head and neck squamous cell carcinomas. Med Sci Monit 2002; 8: BR89-BR94.
31. Kowalski LP, Bagietto R, Lara JR, Santos RL, Silva JF Jr, Magrin J. Prognostic signifcance of the distribution of neck node metastasis from oral carcinoma. Head Neck 2000; 22: 207-214.
32. Fletcher AM, Heaford AC, Trask DK. Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specifc mir-205. Transl Oncol 2008; 1: 202-208.